US Cycle Control and Blood Pressure Study

ClinicalTrials.gov ID: NCT00920985

Public ClinicalTrials.gov record NCT00920985. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 25, 2026, 9:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women

Study identification

NCT ID: NCT00920985
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 346 participants

Conditions and interventions

Conditions

Contraception

Interventions

Gestodene/EE (FC Patch Low, BAY86-5016) Drug
Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 45 Years
Sex: Female
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2009
Primary completion: Jul 31, 2010
Completion: Aug 31, 2010
Last update posted: Oct 8, 2015

2009 – 2010

United States locations

U.S. sites: 28
U.S. states: 16
U.S. cities: 28

Facility	City	State	ZIP	Site status
Not listed	Chandler	Arizona	85225-2909	—
Not listed	Glendale	Arizona	85304	—
Not listed	Phoenix	Arizona	85032	—
Not listed	Tucson	Arizona	85712	—
Not listed	Anaheim	California	92801	—
Not listed	San Diego	California	92121	—
Not listed	Clearwater	Florida	33759	—
Not listed	Daytona Beach	Florida	32114	—
Not listed	Lake Worth	Florida	33461	—
Not listed	Leesburg	Florida	34748	—
Not listed	Miami	Florida	33169	—
Not listed	Atlanta	Georgia	30342	—
Not listed	Decatur	Georgia	30034	—
Not listed	Metairie	Louisiana	70006	—
Not listed	Kalamazoo	Michigan	49009	—
Not listed	St Louis	Missouri	63141	—
Not listed	Las Vegas	Nevada	89104	—
Not listed	New Brunswick	New Jersey	08901	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Cincinnati	Ohio	45246	—
Not listed	Philadelphia	Pennsylvania	19114	—
Not listed	Pittsburgh	Pennsylvania	15206	—
Not listed	Wexford	Pennsylvania	15090	—
Not listed	Columbia	South Carolina	29201	—
Not listed	Richmond	Virginia	23294	—
Not listed	Renton	Washington	98055	—
Not listed	Seattle	Washington	98105	—
Not listed	La Crosse	Wisconsin	54691	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00920985, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 8, 2015 · Synced Jun 25, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00920985 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →